The Malta-based company ICP-Texinfine has established itself as a cutting-edge biotechnology research laboratory, specializing in harnessing the therapeutic properties of plant species to address various organic disorders and deficiencies.
At the request of the Marine Resources Directorate (DRM), ICP-Texinfine has expanded its operations to pearl farming in French Polynesia, joining a research project aimed at improving pearl quality. Simultaneously, the laboratory is working on a program to produce nuclei from powdered local pearl oyster shells, thereby enhancing the independence and sustainability of the pearl industry while boosting local employment.
During recent discussions, Marine Resources Minister Temauri Foster emphasized the importance of ensuring the economic viability of local nucleus production. This need has grown more urgent due to the declining supply of Mississippi mussels, which has significantly impacted global nucleus availability.
Dr. Gilles Gutierrez, CEO of ICP-Texinfine and recipient of the 2009 Louis Pasteur Medal, presented the DRM with a first batch of next-generation reconstituted nuclei. These nuclei will soon undergo grafting tests on pearl oysters, paving the way for a strengthened partnership to position Tahitian pearls as a 100% Polynesian product in the international market.
Beyond its pearl farming research, ICP-Texinfine continues to study Polynesian natural resources. Using extracts from Tahitian vanilla, the company has developed DNA-PKASE INHIBAT, a nutritional supplement with antimutagenic effects. Similarly, research on the algae Padina pavonica has led to the creation of DICTYOLONE, a supplement that promotes bone density and skin health.
Given Polynesia’s exceptional natural resources, ICP-Texinfine is considering establishing a local laboratory dedicated to marine pharmacological formulations. Both the minister and researchers share a common goal: to sustainably and responsibly develop the exploitation of Polynesia’s natural treasures.
Leave a Reply